Home/Pipeline/NCP-based Combination Therapy

NCP-based Combination Therapy

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Coordination Pharmaceuticals

About Coordination Pharmaceuticals

Coordination Pharmaceuticals is an early-stage biotech leveraging a novel nanotechnology platform, Nanoscale Coordination Polymers (NCPs), to create targeted combination therapies for cancer. Founded on research from Professor Wenbin Lin's lab at the University of Chicago, the company focuses on overcoming the limitations of current immuno-oncology treatments by increasing drug delivery to tumors and enhancing T-cell infiltration. As a private, pre-revenue company, its primary goal is to advance its platform through preclinical and clinical development to address unmet needs in solid tumor cancers. Its strategic value lies in the versatility of its NCP platform for co-delivering disparate drug payloads.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active